Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results come from ClinicalTrials.gov. When the live registry is unavailable, a clearly labeled stored copy may be shown.

Clear filters

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Oct 3, 2026, 10:15 PM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 1–24 of 103 matching trials from the live ClinicalTrials.gov search.
Filters: Condition: Methicillin-resistant Staphylococcus Aureus (MRSA) Infection Clear all
Completed Phase 4 Interventional Accepts healthy volunteers

Clinical and Economic Outcomes of Ceftaroline Fosamil for ABSSSI Documented or at Risk of MRSA

NCT02582203
View directory record Official record
Conditions
Skin Diseases, Infectious, Staphylococcal Skin Infections
Interventions
Ceftaroline, Vancomycin
Drug
Lead sponsor
Wayne State University
Other
Eligibility
18 Years to 89 Years
Enrollment
174 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2012 – 2016
U.S. locations
3
States / cities
Detroit, Michigan
Source: ClinicalTrials.gov public record
Updated Nov 1, 2016 · Synced Oct 3, 2026, 10:15 PM EDT
Completed Phase 3 Interventional

Vancomycin Or Trimethoprim/Sulfamethoxazole for Methicillin-resistant Staphylococcus Aureus Osteomyelitis

NCT00324922
View directory record Official record
Conditions
Osteomyelitis, Methicillin-resistant Staphylococcus Aureus
Interventions
trimethoprim-sulfamethoxazole, vancomycin
Drug
Lead sponsor
University of Washington
Other
Eligibility
18 Years and older
Enrollment
2 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2006 – 2007
U.S. locations
1
States / cities
Seattle, Washington
Source: ClinicalTrials.gov public record
Updated Apr 11, 2023 · Synced Oct 3, 2026, 10:15 PM EDT
Completed Phase 4 Interventional

Animal-Assisted Visitation Program Chlorhexidine Trial

NCT04171817
View directory record Official record
Conditions
Methicillin-resistant Staphylococcus Aureus, Clostridium Difficile, Pseudomonas Aeruginosa
Interventions
Chlorhexidine
Drug
Lead sponsor
Johns Hopkins Bloomberg School of Public Health
Other
Eligibility
3 Years to 17 Years
Enrollment
45 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2026
U.S. locations
3
States / cities
Baltimore, Maryland • St Louis, Missouri • Philadelphia, Pennsylvania
Source: ClinicalTrials.gov public record
Updated May 1, 2026 · Synced Oct 3, 2026, 10:15 PM EDT
Completed Phase 3 Interventional Results available

Comparative Study of Ceftaroline vs. Vancomycin Plus Aztreonam in Adult Subjects With Complicated Skin Infections

NCT00424190
View directory record Official record
Conditions
Bacterial Infections
Interventions
IV Vancomycin plus IV Aztreonam, Ceftaroline
Drug
Lead sponsor
Forest Laboratories
Industry
Eligibility
18 Years and older
Enrollment
698 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2007
U.S. locations
15
States / cities
Dothan, Alabama • Long Beach, California • Los Angeles, California + 11 more
Source: ClinicalTrials.gov public record
Updated Mar 14, 2017 · Synced Oct 3, 2026, 10:15 PM EDT
Completed Phase 3 Interventional Results available

Comparative Study of Ceftaroline vs. Vancomycin Plus Aztreonam in Adult Subjects With Complicated Skin Infections

NCT00423657
View directory record Official record
Conditions
Bacterial Infections
Interventions
ceftaroline, vancomycin plus aztreonam, Placebo
Drug
Lead sponsor
Forest Laboratories
Industry
Eligibility
18 Years and older
Enrollment
680 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2007
U.S. locations
17
States / cities
Buena Park, California • Hawaiian Gardens, California • Los Angeles, California + 14 more
Source: ClinicalTrials.gov public record
Updated Mar 14, 2017 · Synced Oct 3, 2026, 10:15 PM EDT
Completed Phase 3 Interventional Results available

AeroVanc in the Treatment of Methicillin-resistant Staphylococcus Aureus Infection in Patients With Cystic Fibrosis

NCT03181932
View directory record Official record
Conditions
MRSA, Cystic Fibrosis
Interventions
Vancomycin inhalation powder, Placebo inhalation powder
Drug
Lead sponsor
Savara Inc.
Industry
Eligibility
6 Years and older
Enrollment
188 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2021
U.S. locations
69
States / cities
Mobile, Alabama • Phoenix, Arizona • Little Rock, Arkansas + 62 more
Source: ClinicalTrials.gov public record
Updated Dec 16, 2022 · Synced Oct 3, 2026, 10:15 PM EDT
Completed Not applicable Interventional Accepts healthy volunteers

A Prospective Cohort Pilot Study of the Clinical and Molecular Epidemiology of Staphylococcus Aureus in Pregnant Women at the Time of Group B Streptococcal Screening in a Large Urban Medical Center in Chicago, IL USA

NCT00532324
View directory record Official record
Conditions
Staphylococcus Aureus
Interventions
CA-MRSA Decolonization
Other
Lead sponsor
Ann & Robert H Lurie Children's Hospital of Chicago
Other
Eligibility
Female only
Enrollment
107 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2008 – 2013
U.S. locations
1
States / cities
Chicago, Illinois
Source: ClinicalTrials.gov public record
Updated Mar 28, 2025 · Synced Oct 3, 2026, 10:15 PM EDT
Completed Phase 2 Interventional Results available

STaph Aureus Resistance-Treat Early and Repeat (STAR-TER)

NCT03489629
View directory record Official record
Conditions
Cystic Fibrosis
Interventions
Trimethoprim Sulfamethoxazole (TMP/SMX), Minocycline, Mupirocin, Chlorhexidine Gluconate, Environmental Decontamination
Drug · Behavioral
Lead sponsor
University of North Carolina, Chapel Hill
Other
Eligibility
2 Years to 45 Years
Enrollment
49 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2026
U.S. locations
9
States / cities
Denver, Colorado • Indianapolis, Indiana • Ann Arbor, Michigan + 6 more
Source: ClinicalTrials.gov public record
Updated Sep 15, 2026 · Synced Oct 3, 2026, 10:15 PM EDT
Completed Not applicable Interventional Accepts healthy volunteers Results available

Building an Optimal Hand Hygiene Bundle

NCT02223455
View directory record Official record
Conditions
Hand Hygiene, Health Care Associated Infection, Compliance
Interventions
Hand Hygiene Signs
Other
Lead sponsor
VA Office of Research and Development
Federal
Eligibility
18 Years and older
Enrollment
58 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2014 – 2019
U.S. locations
10
States / cities
Miami, Florida • Iowa City, Iowa • Baltimore, Maryland + 7 more
Source: ClinicalTrials.gov public record
Updated Oct 4, 2019 · Synced Oct 3, 2026, 10:15 PM EDT
Completed No phase listed Observational

Initial and Chronic Methicillin Resistant Staphylococcus Aureus (MRSA) Infection in Cystic Fibrosis (CF)

NCT02684422
View directory record Official record
Conditions
Methicillin-Resistant Staphylococcus Aureus, Cystic Fibrosis
Interventions
Intervention N/A. Observational study
Other
Lead sponsor
University of North Carolina, Chapel Hill
Other
Eligibility
4 Years to 99 Years
Enrollment
48 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2015 – 2021
U.S. locations
3
States / cities
Birmingham, Alabama • Chapel Hill, North Carolina • Seattle, Washington
Source: ClinicalTrials.gov public record
Updated Jan 20, 2022 · Synced Oct 3, 2026, 10:15 PM EDT
Terminated Phase 4 Interventional Results available

A Pilot Study of Daptomycin for Antimicrobial Prophylaxis

NCT00572260
View directory record Official record
Conditions
Antimicrobial Prophylaxis
Interventions
daptomycin 6 mg/kg IV
Drug
Lead sponsor
Duke University
Other
Eligibility
18 Years and older
Enrollment
11 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2008
U.S. locations
1
States / cities
Durham, North Carolina
Source: ClinicalTrials.gov public record
Updated Jul 25, 2014 · Synced Oct 3, 2026, 10:15 PM EDT
Completed Phase 3 Interventional Accepts healthy volunteers Results available

Prospective Randomized Trial of Bactrim on 7 Day Outcome in Patients With Uncomplicated Abscesses

NCT00973765
View directory record Official record
Conditions
Abscesses
Interventions
bactrim, placebo
Drug
Lead sponsor
59th Medical Wing
Federal
Eligibility
16 Years and older
Enrollment
212 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2007 – 2009
U.S. locations
1
States / cities
Lackland Air Force Base, Texas
Source: ClinicalTrials.gov public record
Updated Mar 9, 2010 · Synced Oct 3, 2026, 10:15 PM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

Safety and Pharmacokinetics of Ascending Single Oral Doses of EDP-322 in Nonfasting and Fasting Healthy Volunteers

NCT00989872
View directory record Official record
Conditions
Skin and Soft Tissue Infections, Methicillin-resistant Staphylococcus Aureus
Interventions
EDP-322
Drug
Lead sponsor
Enanta Pharmaceuticals, Inc
Industry
Eligibility
18 Years to 45 Years
Enrollment
67 participants
Healthy volunteers
Accepts healthy volunteers
U.S. locations
1
States / cities
Austin, Texas
Source: ClinicalTrials.gov public record
Updated Oct 6, 2009 · Synced Oct 3, 2026, 10:15 PM EDT
No Longer Available No phase listed Expanded access Accepts healthy volunteers

Direct Antibiotic Delivery of Cefazolin Into Soft Tissue Infections Using Subcutaneous Injection and Ultrasonic Dispersion

NCT01238276
View directory record Official record
Conditions
Infection, Soft Tissue, Infection, Wound, Cellulitis, Diabetic Foot Ulcer
Interventions
Cefazolin, Silberg Tissue Preparation System
Drug · Device
Lead sponsor
Sonescence, Inc.
Industry
Eligibility
18 Years and older
Healthy volunteers
Accepts healthy volunteers
U.S. locations
1
States / cities
Sebastopol, California
Source: ClinicalTrials.gov public record
Updated Oct 23, 2018 · Synced Oct 3, 2026, 10:15 PM EDT
Completed Phase 3 Interventional Results available

Comparison of Telavancin and Vancomycin for Hospital-acquired Pneumonia Due to Methicillin-resistant Staphylococcus Aureus

NCT00107952
View directory record Official record
Conditions
Bacterial Pneumonia
Interventions
Telavancin, Vancomycin
Drug
Lead sponsor
Cumberland Pharmaceuticals
Industry
Eligibility
18 Years and older
Enrollment
761 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2005 – 2007
U.S. locations
1
States / cities
Springfield, Massachusetts
Source: ClinicalTrials.gov public record
Updated Jan 16, 2019 · Synced Oct 3, 2026, 10:15 PM EDT
Terminated Phase 2 Interventional Results available

Phase 2 Study of Safety, Efficacy, and Pharmacokinetics of Higher Doses of Daptomycin and Vancomycin in MRSA Bacteremia

NCT00695903
View directory record Official record
Conditions
Endocarditis, Bacterial, Infective Endocarditis
Interventions
daptomycin, vancomycin
Drug
Lead sponsor
Cubist Pharmaceuticals LLC, a subsidiary of Merck & Co., Inc. (Rahway, New Jersey USA)
Industry
Eligibility
18 Years and older
Enrollment
38 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2008 – 2010
U.S. locations
2
States / cities
Greenville, North Carolina • Cleveland, Ohio
Source: ClinicalTrials.gov public record
Updated Dec 24, 2018 · Synced Oct 3, 2026, 10:15 PM EDT
Completed No phase listed Observational Results available

Gown and Glove Use to Prevent the Spread of Infection in VA Community Living Centers

NCT01350479
View directory record Official record
Conditions
Methicillin-Resistant Staphylococcus Aureus
Interventions
Not listed
Lead sponsor
VA Office of Research and Development
Federal
Eligibility
18 Years and older
Enrollment
203 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2012 – 2016
U.S. locations
7
States / cities
Washington D.C., District of Columbia • Baltimore, Maryland • Perry Point, Maryland + 3 more
Source: ClinicalTrials.gov public record
Updated Oct 5, 2017 · Synced Oct 3, 2026, 10:15 PM EDT
Completed Phase 1Phase 2 Interventional Accepts healthy volunteers Results available

Staphylococcus Aureus Toxoids Phase 1-2 Vaccine Trial

NCT01011335
View directory record Official record
Conditions
Staphylococcus Aureus
Interventions
Monovalent rAT, Monovalent rLukS-PV, Bivalent rLukS-PV / rAT, Placebo with adjuvant, Placebo
Biological
Lead sponsor
Henry M. Jackson Foundation for the Advancement of Military Medicine
Other
Eligibility
18 Years to 55 Years
Enrollment
176 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2009 – 2011
U.S. locations
2
States / cities
Fort Sam Houston, Texas • Portsmouth, Virginia
Source: ClinicalTrials.gov public record
Updated Mar 7, 2023 · Synced Oct 3, 2026, 10:15 PM EDT
Completed Not applicable Interventional

Comparison of Standard Isolation With Targeted Isolation for Preventing Nosocomial Transmission of MRSA and VRE

NCT03268122
View directory record Official record
Conditions
MRSA, VRE Infection
Interventions
Standard Contact Isolation, Targeted Contact Isolation
Other
Lead sponsor
Vanderbilt University Medical Center
Other
Eligibility
18 Years and older
Enrollment
1,974 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2018
U.S. locations
1
States / cities
Nashville, Tennessee
Source: ClinicalTrials.gov public record
Updated Jun 14, 2018 · Synced Oct 3, 2026, 10:15 PM EDT
Completed Phase 4 Interventional Results available

Povidone-Iodine for Nasal Decolonization

NCT05529173
View directory record Official record
Conditions
Surgical Wound Infection, Preoperative Care, Methicillin-Resistant Staphylococcus Aureus
Interventions
Povidone-Iodine 10%, 0.9% NaCl Solution
Drug
Lead sponsor
Rutgers, The State University of New Jersey
Other
Eligibility
18 Years to 80 Years
Enrollment
192 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022 – 2023
U.S. locations
1
States / cities
Newark, New Jersey
Source: ClinicalTrials.gov public record
Updated Nov 13, 2024 · Synced Oct 3, 2026, 10:15 PM EDT
Completed No phase listed Observational Accepts healthy volunteers

Volatile Organic Compounds in Staphylococcus Aureus Patients

NCT01379053
View directory record Official record
Conditions
Staphylococcus Aureus, Methicillin-resistant Staphylococcus Aureus, Nosocomial Disease
Interventions
Not listed
Lead sponsor
Landon Pediatric Foundation
Other
Eligibility
1 Year to 85 Years
Enrollment
10 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2009 – 2010
U.S. locations
1
States / cities
Ventura, California
Source: ClinicalTrials.gov public record
Updated Aug 13, 2014 · Synced Oct 3, 2026, 10:15 PM EDT
Withdrawn Phase 4 Interventional

Ceftaroline in the Treatment of Bone and Joint Infections

NCT02005068
View directory record Official record
Conditions
Osteomyelitis, Joint Infections
Interventions
Ceftaroline
Drug
Lead sponsor
Orlando Health, Inc.
Other
Eligibility
18 Years and older
Healthy volunteers
Healthy volunteers not accepted
Timeline
2013 – 2014
U.S. locations
1
States / cities
Orlando, Florida
Source: ClinicalTrials.gov public record
Updated Aug 7, 2014 · Synced Oct 3, 2026, 10:15 PM EDT
Terminated Phase 2 Interventional Results available

Early Methicillin-resistant Staphylococcus Aureus (MRSA) Therapy in Cystic Fibrosis (CF)

NCT01349192
View directory record Official record
Conditions
Cystic Fibrosis, Methicillin-resistant Staphylococcus Aureus
Interventions
Rifampin, Trimethoprim/Sulfamethoxazole, Minocycline, Mupirocin, chlorhexidine gluconate oral rinse, 2% Chlorhexidine solution wipes, Environmental Decontamination
Drug · Behavioral
Lead sponsor
University of North Carolina, Chapel Hill
Other
Eligibility
4 Years to 45 Years
Enrollment
47 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2011 – 2015
U.S. locations
13
States / cities
Birmingham, Alabama • Aurora, Colorado • Gainesville, Florida + 9 more
Source: ClinicalTrials.gov public record
Updated May 15, 2017 · Synced Oct 3, 2026, 10:15 PM EDT
Terminated Not applicable Interventional Results available

Randomized Controlled Trial of Antibiotics in the Management of Children With Community-Acquired Abscess

NCT01498744
View directory record Official record
Conditions
Abscess Soft Tissue, Methicillin-resistant Staphylococcus Aureus (MRSA) Infection, Skin Abscess
Interventions
Oral Clindamycin
Drug
Lead sponsor
Ann & Robert H Lurie Children's Hospital of Chicago
Other
Eligibility
1 Month to 17 Years
Enrollment
53 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2010 – 2013
U.S. locations
1
States / cities
Chicago, Illinois
Source: ClinicalTrials.gov public record
Updated Feb 25, 2016 · Synced Oct 3, 2026, 10:15 PM EDT